Table 14.10

De Novo Post Transplant Solid Malignancy, 1997 to 2006

Heart Recipients

Malignancies by Type Year of Transplant
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Total # of Post-Tx Malignancies 563 488 368 344 256 182 129 84 48 4
Squamous/Basal Cell Carcinoma 366 287 217 179 150 100 83 45 29 4
Melanoma 23 20 18 13 9 5 8 6 1 -
Kaposi Sarcoma 1 3 1 - 1 - - - - -
Central Nervous System 1 4 4 3 - - - - - -
Genito-Urinary (1) 51 60 46 52 36 23 15 19 6 -
Gastro-Intestinal (2) 16 14 13 20 11 11 10 1 4 -
Primary Hepatic Tumor 4 2 1 2 2 - - - - -
Metastatic Hepatic Tumor 2 4 4 4 2 4 1 - 1 -
Larynx/Bronchi/Lung 59 47 43 35 26 20 5 8 2 -
Breast/Thyroid 11 18 9 6 9 4 4 4 - -
Leukemia 3 3 2 - - 2 - - - -
Sarcoma (3) 1 1 - 2 - 3 - - - -
Other 21 20 8 24 9 10 2 1 5 -
Unknown 4 5 2 4 1 - 1 - - -
Squamous/Basal Cell Carcinoma 65.0% 58.8% 59.0% 52.0% 58.6% 54.9% 64.3% 53.6% 60.4% 100.0%
Melanoma 4.1% 4.1% 4.9% 3.8% 3.5% 2.7% 6.2% 7.1% 2.1% -
Kaposi Sarcoma 0.2% 0.6% 0.3% - 0.4% - - - - -
Central Nervous System 0.2% 0.8% 1.1% 0.9% - - - - - -
Genito-Urinary (1) 9.1% 12.3% 12.5% 15.1% 14.1% 12.6% 11.6% 22.6% 12.5% -
Gastro-Intestinal (2) 2.8% 2.9% 3.5% 5.8% 4.3% 6.0% 7.8% 1.2% 8.3% -
Primary Hepatic Tumor 0.7% 0.4% 0.3% 0.6% 0.8% - - - - -
Metastatic Hepatic Tumor 0.4% 0.8% 1.1% 1.2% 0.8% 2.2% 0.8% - 2.1% -
Larynx/Bronchi/Lung 10.5% 9.6% 11.7% 10.2% 10.2% 11.0% 3.9% 9.5% 4.2% -
Breast/Thyroid 2.0% 3.7% 2.4% 1.7% 3.5% 2.2% 3.1% 4.8% - -
Leukemia 0.5% 0.6% 0.5% - - 1.1% - - - -
Sarcoma (3) 0.2% 0.2% - 0.6% - 1.6% - - - -
Other 3.7% 4.1% 2.2% 7.0% 3.5% 5.5% 1.6% 1.2% 10.4% -
Unknown 0.7% 1.0% 0.5% 1.2% 0.4% - 0.8% - - -
Total # of Patients 335 302 244 223 174 132 92 70 36 3


Source: OPTN/SRTR Data as of May 1, 2007.

(-) = None in category.

(1) Genito-Urinary: kidney, bladder, uterine cervix, uterine body, ovarian, vulva, testicular, prostate.

(2) Gastro-Intestinal: tongue, throat, esophagus, stomach, small intestine, colo-rectal, liver and biliary tract, pancreas.

(3) Sarcoma: fibrosarcoma, osteosarcoma, etc.

Recipient malignancy statistics are based on voluntary reporting to the OPTN.